Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Ipamorelin cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established Ipamorelin cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Ipamorelin combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Ipamorelin cycle length?
No. We found no human studies that report a treatment duration for Ipamorelin.
What is the longest human study of Ipamorelin?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Ipamorelin dosing reference Full research page

References

  1. Ipamorelin, the first selective growth hormone secretagogue Eur J Endocrinol. 1998
  2. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus J Pharmacol Exp Ther. 2009
  3. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers Pharm Res. 1999
  4. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients Int J Colorectal Dis. 2014
  5. Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus (NCT00672074) ClinicalTrials.gov. 2008
  6. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function (NCT01280344) ClinicalTrials.gov. 2011
  7. FDA Briefing Document: Ipamorelin-related bulk drug substances, Pharmacy Compounding Advisory Committee, October 29, 2024 FDA. 2024
  8. Substances in Compounding that May Present Significant Safety Risks FDA. 2024
  9. WADA Prohibited List US Food and Drug Administration. 2026
  10. Ipamorelin (CID 9831659) PubChem. 2026
  11. DailyMed drug label search for ipamorelin (zero labels returned on 22 Oct 2026) DailyMed (NLM). 2026